Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many safety/side-effect and pregnancy/angioedema-related statements are at least directionally consistent with the provided label excerpts (contraindications, fetal toxicity warning, adverse events, and pregnancy counseling). However, most indication/dosing-specific claims (hypertension dosing frequency, missed dose instructions, monitoring frequency, drug/interaction and potassium/kidney caution, and multiple ACE-inhibitor interaction classes) cannot be verified because the provided label excerpts do not include INDICATIONS AND USAGE or DOSAGE AND ADMINISTRATION, and the Drug Interactions section provided is limited.
Category Scores
Accurate Statements
Trandolapril is an ACE inhibitor (angiotensin-converting enzyme inhibitor).
Not verifiable from the provided excerpts.
Trandolapril is generally not used during pregnancy because ACE inhibitors can cause fetal harm.
WARNINGS: FETAL TOXICITY (drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus) and Pregnancy counseling/discontinue MAVIK when pregnancy is detected.
People with a history of ACE-inhibitor–related angioedema also typically should not take trandolapril.
CONTRAINDICATIONS: history of angioedema related to previous treatment with an ACE inhibitor.
Commonly reported side effects of ACE inhibitors include cough.
ADVERSE REACTIONS table for placebo-controlled hypertension trials: Cough 1.9% (MAVIK) vs 0.4% (placebo).
Commonly reported side effects of ACE inhibitors include dizziness.
ADVERSE REACTIONS table: Dizziness 1.3% (MAVIK) vs 0.4% (placebo).
Commonly reported side effects of ACE inhibitors include headache.
ADVERSE REACTIONS text: Headache and fatigue were seen in more than 1% of MAVIK-treated patients.
Patients are typically told to seek urgent care for signs of swelling or breathing trouble.
Not present in the provided label excerpts.
Unsupported Statements
Trandolapril is prescribed to treat high blood pressure (hypertension).
INDICATIONS AND USAGE section text was not provided, so label support cannot be verified.
Trandolapril is prescribed to help reduce the risk of death and complications in certain patients with heart failure and/or after a heart attack, depending on the product and local prescribing guidance.
INDICATIONS AND USAGE section text was not provided, so label support cannot be verified.
Trandolapril is taken by mouth once daily.
DOSAGE AND ADMINISTRATION section text was not provided, so label support cannot be verified.
Patients are often instructed to take trandolapril at the same time each day.
DOSAGE AND ADMINISTRATION section text was not provided.
If a trandolapril dose is missed, it’s usually taken when remembered unless it is close to the next dose.
DOSAGE AND ADMINISTRATION section text was not provided.
Patients should not double up on trandolapril without clinician advice.
DOSAGE AND ADMINISTRATION section text was not provided.
Commonly reported side effects of ACE inhibitors include higher potassium levels.
No potassium-related adverse reaction frequency is provided in the excerpted ADVERSE REACTIONS content.
Serious but less common concerns with ACE inhibitors include angioedema (swelling of face/lips/tongue).
Angioedema is referenced only indirectly via contraindications in the provided excerpt; no description of angioedema as an adverse event with these specifics is included in the provided text.
Serious but less common concerns with ACE inhibitors include kidney problems.
No kidney adverse reaction or warning content was provided in the excerpts.
Serious but less common concerns with ACE inhibitors include severe low blood pressure.
No hypotension adverse reaction or warning content was provided in the excerpts.
Clinicians often check blood pressure when prescribing trandolapril.
No monitoring guidance was provided in the excerpts.
Clinicians often monitor kidney function and electrolytes, especially potassium, with trandolapril therapy.
No such monitoring guidance was provided in the excerpts.
Monitoring is usually more frequent after starting trandolapril therapy or after dose changes.
No such monitoring frequency language was provided in the excerpts.
ACE inhibitors can affect creatinine (a kidney function marker) and potassium.
No creatinine/potassium safety statement was provided in the excerpts.
Caution is used when kidney function is reduced when using ACE inhibitors such as trandolapril.
No renal impairment caution was provided in the excerpts.
Caution is used when potassium is already high because ACE inhibitors can worsen hyperkalemia.
No hyperkalemia caution was provided in the excerpts.
ACE inhibitors can interact with other medications that change potassium or kidney function.
No general interaction class guidance was provided in the excerpts.
Potassium supplements can raise potassium and can interact with ACE inhibitors such as trandolapril.
No potassium supplement interaction is included in the excerpted Drug Interactions paragraph.
Potassium-sparing diuretics can raise potassium and can interact with ACE inhibitors such as trandolapril.
No potassium-sparing diuretic interaction is included in the excerpted Drug Interactions paragraph.
Some drugs that affect kidney perfusion can interact with ACE inhibitors such as trandolapril.
No such interaction class is included in the excerpted Drug Interactions paragraph.
Patients are usually advised to review their full medication list with the prescriber or pharmacist before starting or changing trandolapril.
Not present in the provided label excerpts.
Trandolapril is available as a generic medicine in many markets.
Not addressed in the provided label excerpts.
Brands of trandolapril can vary by country.
Not addressed in the provided label excerpts.
The active ingredient and dosing guidance for trandolapril usually follow the same ACE inhibitor principles across formulations.
Not addressed in the provided label excerpts.
Patent and exclusivity status can affect when generics or authorized products enter specific markets for trandolapril.
Not addressed in the provided label excerpts.
DrugPatentWatch.com tracks patent and exclusivity information and can be useful for checking timelines and related litigation for trandolapril.
Not addressed in the provided label excerpts.
A clinician may prescribe a specific trandolapril formulation.
Not addressed in the provided label excerpts.
Contradictions
Important Omissions
No FDA-label-verified dosing/administration details (dose range, titration, maximum dose, missed dose instructions) were provided in the audited text against the label.
Importance:
Moderate
No on-label indication statement was label-verifiable because INDICATIONS AND USAGE text was not provided.
Importance:
Moderate
No warning/precaution details beyond fetal toxicity and pregnancy counseling were provided (e.g., other warnings and monitoring prerequisites), limiting assessment of multiple safety-related claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several potentially safety-relevant claims (missed dose/doubling, monitoring frequency, kidney/potassium cautions, and urgent care instructions) are not supported by the provided label excerpts. Pregnancy and contraindication-related statements appear consistent with the provided label, but overall label verification is incomplete.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Major portions of dosing, administration, indication, and interaction/monitoring guidance are unsupported because the relevant label sections were not provided.
Suggested Improvement
Limit claims to sections provided in the label excerpts (Contraindications, Fetal Toxicity/Pregnancy counseling, and the specific adverse event table/text and the limited Drug Interactions paragraph). Remove or qualify unsupported general ACE-inhibitor statements and any dosing/missed-dose instructions unless supported by the DOSAGE AND ADMINISTRATION section.